ES2279162T3 - Nuevos purin- o pirrolo(2,3-d)pirimidin-2-carbonitrilos para tratar enfermedades asociadas con actividad de cisteina proteasa. - Google Patents
Nuevos purin- o pirrolo(2,3-d)pirimidin-2-carbonitrilos para tratar enfermedades asociadas con actividad de cisteina proteasa. Download PDFInfo
- Publication number
- ES2279162T3 ES2279162T3 ES03761002T ES03761002T ES2279162T3 ES 2279162 T3 ES2279162 T3 ES 2279162T3 ES 03761002 T ES03761002 T ES 03761002T ES 03761002 T ES03761002 T ES 03761002T ES 2279162 T3 ES2279162 T3 ES 2279162T3
- Authority
- ES
- Spain
- Prior art keywords
- carbonitrile
- purin
- chlorophenyl
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000010099 disease Diseases 0.000 title description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 6
- 108010005843 Cysteine Proteases Proteins 0.000 title description 5
- 102000005927 Cysteine Proteases Human genes 0.000 title description 5
- 230000000694 effects Effects 0.000 title description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 48
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 39
- 239000001257 hydrogen Substances 0.000 claims abstract description 38
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 28
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 28
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 26
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 20
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 17
- -1 amino, hydroxy Chemical group 0.000 claims abstract description 16
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 14
- 125000003118 aryl group Chemical group 0.000 claims abstract description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 13
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 9
- 125000004429 atom Chemical group 0.000 claims abstract description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 4
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 3
- 239000012453 solvate Substances 0.000 claims abstract description 3
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 3
- 125000005843 halogen group Chemical group 0.000 claims abstract 6
- CDLFCUGNXCSXKZ-UHFFFAOYSA-N 7-(4-chlorophenyl)-4-morpholin-4-ylpyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2C=C1 CDLFCUGNXCSXKZ-UHFFFAOYSA-N 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 8
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- OHYNGDSTLQYXLP-UHFFFAOYSA-N 4-(4-chloroanilino)-7-ethylpyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C2N(CC)C=CC2=C1NC1=CC=C(Cl)C=C1 OHYNGDSTLQYXLP-UHFFFAOYSA-N 0.000 claims description 4
- KJGSMDDJESIJNG-UHFFFAOYSA-N 6-(4-chloroanilino)-9-ethylpurine-2-carbonitrile Chemical compound N1=C(C#N)N=C2N(CC)C=NC2=C1NC1=CC=C(Cl)C=C1 KJGSMDDJESIJNG-UHFFFAOYSA-N 0.000 claims description 4
- BWHVBFJJBFQDHY-UHFFFAOYSA-N 9-(2-chlorophenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound ClC1=CC=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 BWHVBFJJBFQDHY-UHFFFAOYSA-N 0.000 claims description 4
- XUIHMMWMTLPFOD-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 XUIHMMWMTLPFOD-UHFFFAOYSA-N 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- DBYOJBZTUZLETB-UHFFFAOYSA-N 1-(4-methylphenyl)-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidine-6-carbonitrile Chemical compound C1=CC(C)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2C=N1 DBYOJBZTUZLETB-UHFFFAOYSA-N 0.000 claims description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
- HIZRIHSRKDKKSH-UHFFFAOYSA-N 6-morpholin-4-yl-9-(4-propan-2-ylphenyl)purine-2-carbonitrile Chemical compound C1=CC(C(C)C)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 HIZRIHSRKDKKSH-UHFFFAOYSA-N 0.000 claims description 3
- PCLZMBYSLWKOAK-UHFFFAOYSA-N 7-(4-chlorophenyl)-4-(ethylamino)pyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound C1=CC=2C(NCC)=NC(C#N)=NC=2N1C1=CC=C(Cl)C=C1 PCLZMBYSLWKOAK-UHFFFAOYSA-N 0.000 claims description 3
- TUXPZXDUIDXMKS-UHFFFAOYSA-N 7-(4-methoxyphenyl)-4-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C(N=C(N=C2N3CCOCC3)C#N)=C2CC1 TUXPZXDUIDXMKS-UHFFFAOYSA-N 0.000 claims description 3
- XNGFLKZGUISSFI-UHFFFAOYSA-N 7-(4-methoxyphenyl)-4-pyrrolidin-1-yl-5,6-dihydropyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C(N=C(N=C2N3CCCC3)C#N)=C2CC1 XNGFLKZGUISSFI-UHFFFAOYSA-N 0.000 claims description 3
- SADXVLLLVZNAIE-UHFFFAOYSA-N 8-amino-6-(4-chloroanilino)-9-ethylpurine-2-carbonitrile Chemical compound N1=C(C#N)N=C2N(CC)C(N)=NC2=C1NC1=CC=C(Cl)C=C1 SADXVLLLVZNAIE-UHFFFAOYSA-N 0.000 claims description 3
- YMNMAQWGBPDRTK-UHFFFAOYSA-N 8-amino-9-(4-chlorophenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound NC1=NC2=C(N3CCOCC3)N=C(C#N)N=C2N1C1=CC=C(Cl)C=C1 YMNMAQWGBPDRTK-UHFFFAOYSA-N 0.000 claims description 3
- MVVBRPYXMOZGKI-UHFFFAOYSA-N 9-(3,4-difluorophenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound C1=C(F)C(F)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 MVVBRPYXMOZGKI-UHFFFAOYSA-N 0.000 claims description 3
- VBGBBKIHTJHISX-UHFFFAOYSA-N 9-(3-chlorophenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound ClC1=CC=CC(N2C3=NC(=NC(=C3N=C2)N2CCOCC2)C#N)=C1 VBGBBKIHTJHISX-UHFFFAOYSA-N 0.000 claims description 3
- IUNJCEDNJBYIJD-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-(4-pyrrolidin-1-ylpiperidin-1-yl)purine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(N3CCC(CC3)N3CCCC3)=C2N=C1 IUNJCEDNJBYIJD-UHFFFAOYSA-N 0.000 claims description 3
- CDHQZBPHQBCKQV-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-(dimethylamino)purine-2-carbonitrile Chemical compound C1=NC=2C(N(C)C)=NC(C#N)=NC=2N1C1=CC=C(Cl)C=C1 CDHQZBPHQBCKQV-UHFFFAOYSA-N 0.000 claims description 3
- RFQMESZAJFZUBR-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-(ethylamino)purine-2-carbonitrile Chemical compound C1=NC=2C(NCC)=NC(C#N)=NC=2N1C1=CC=C(Cl)C=C1 RFQMESZAJFZUBR-UHFFFAOYSA-N 0.000 claims description 3
- WMCPEBXOCLBPGC-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-morpholin-4-yl-8-oxo-7h-purine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C(=O)NC2=C(N3CCOCC3)N=C(C#N)N=C21 WMCPEBXOCLBPGC-UHFFFAOYSA-N 0.000 claims description 3
- UOMTYTKUUJJIBQ-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-piperazin-1-ylpurine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(N3CCNCC3)=C2N=C1 UOMTYTKUUJJIBQ-UHFFFAOYSA-N 0.000 claims description 3
- WIVBKPYLSWPJQG-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-pyrrolidin-1-ylpurine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(N3CCCC3)=C2N=C1 WIVBKPYLSWPJQG-UHFFFAOYSA-N 0.000 claims description 3
- PJKVLYWRACWXQS-UHFFFAOYSA-N 9-(4-chlorophenyl)-8-(dimethylamino)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound CN(C)C1=NC2=C(N3CCOCC3)N=C(C#N)N=C2N1C1=CC=C(Cl)C=C1 PJKVLYWRACWXQS-UHFFFAOYSA-N 0.000 claims description 3
- SGVMUUDCZGWPHJ-UHFFFAOYSA-N 9-(4-methoxyphenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 SGVMUUDCZGWPHJ-UHFFFAOYSA-N 0.000 claims description 3
- HOVKNKINGXLBAW-UHFFFAOYSA-N 9-(4-methoxyphenyl)-6-pyrrolidin-1-ylpurine-2-carbonitrile Chemical compound C1=CC(OC)=CC=C1N1C2=NC(C#N)=NC(N3CCCC3)=C2N=C1 HOVKNKINGXLBAW-UHFFFAOYSA-N 0.000 claims description 3
- ZGNVAGDTSYPAJB-UHFFFAOYSA-N 9-(4-methylphenyl)-6-pyrrolidin-1-ylpurine-2-carbonitrile Chemical compound C1=CC(C)=CC=C1N1C2=NC(C#N)=NC(N3CCCC3)=C2N=C1 ZGNVAGDTSYPAJB-UHFFFAOYSA-N 0.000 claims description 3
- GCLKFJUHXFRUKP-UHFFFAOYSA-N 9-(4-methylsulfonylphenyl)-6-morpholin-4-ylpurine-2-carbonitrile Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C2=NC(C#N)=NC(N3CCOCC3)=C2N=C1 GCLKFJUHXFRUKP-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- ILVKKBYDRWXMGO-UHFFFAOYSA-N 6-(2-aminoethylamino)-9-(4-chlorophenyl)purine-2-carbonitrile Chemical compound C1=NC=2C(NCCN)=NC(C#N)=NC=2N1C1=CC=C(Cl)C=C1 ILVKKBYDRWXMGO-UHFFFAOYSA-N 0.000 claims description 2
- IJLSEYBZVOUGOY-UHFFFAOYSA-N 6-(4-aminopiperidin-1-yl)-9-(4-chlorophenyl)purine-2-carbonitrile Chemical compound C1CC(N)CCN1C1=NC(C#N)=NC2=C1N=CN2C1=CC=C(Cl)C=C1 IJLSEYBZVOUGOY-UHFFFAOYSA-N 0.000 claims description 2
- JQODVNYFMAKYFL-UHFFFAOYSA-N 9-(4-chlorophenyl)-6-(3-pyrrolidin-1-ylpropylamino)purine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(C#N)=NC(NCCCN3CCCC3)=C2N=C1 JQODVNYFMAKYFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- VKVJIWVUYNTBEZ-UHFFFAOYSA-N 1,3-bis(3,5-dichlorophenyl)urea Chemical compound ClC1=CC(Cl)=CC(NC(=O)NC=2C=C(Cl)C=C(Cl)C=2)=C1 VKVJIWVUYNTBEZ-UHFFFAOYSA-N 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 60
- 239000000203 mixture Substances 0.000 description 57
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 35
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 34
- 239000000047 product Substances 0.000 description 33
- 239000000243 solution Substances 0.000 description 33
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 30
- 235000019341 magnesium sulphate Nutrition 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 238000004587 chromatography analysis Methods 0.000 description 17
- 239000000377 silicon dioxide Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 13
- 229910052708 sodium Inorganic materials 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 8
- 108090000613 Cathepsin S Proteins 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 102100035654 Cathepsin S Human genes 0.000 description 7
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 150000002367 halogens Chemical group 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- IRUNKQSGDBYUDC-UHFFFAOYSA-N diethoxymethyl acetate Chemical compound CCOC(OCC)OC(C)=O IRUNKQSGDBYUDC-UHFFFAOYSA-N 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- 229940001584 sodium metabisulfite Drugs 0.000 description 3
- 235000010262 sodium metabisulphite Nutrition 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- VCOVUYXJMHMVNV-FMYROPPKSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C(=O)OCC1=CC=CC=C1 VCOVUYXJMHMVNV-FMYROPPKSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004820 halides Chemical group 0.000 description 2
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- RXPZJYKGHXZIEJ-UHFFFAOYSA-N 2,4,6-trichloro-5-prop-2-enylpyrimidine Chemical compound ClC1=NC(Cl)=C(CC=C)C(Cl)=N1 RXPZJYKGHXZIEJ-UHFFFAOYSA-N 0.000 description 1
- KCKPMJHDDVWLLL-UHFFFAOYSA-N 2,4-dichloro-7-(4-chlorophenyl)pyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(Cl)=CC=C1N1C2=NC(Cl)=NC(Cl)=C2C=C1 KCKPMJHDDVWLLL-UHFFFAOYSA-N 0.000 description 1
- RMFWVOLULURGJI-UHFFFAOYSA-N 2,6-dichloro-7h-purine Chemical compound ClC1=NC(Cl)=C2NC=NC2=N1 RMFWVOLULURGJI-UHFFFAOYSA-N 0.000 description 1
- UVBZEMOEZNCZRE-UHFFFAOYSA-N 2-[2,4-dichloro-6-(4-chloroanilino)pyrimidin-5-yl]acetaldehyde Chemical compound C1=CC(Cl)=CC=C1NC1=NC(Cl)=NC(Cl)=C1CC=O UVBZEMOEZNCZRE-UHFFFAOYSA-N 0.000 description 1
- IBCZOXNKMXUTOG-UHFFFAOYSA-N 2-chloro-n-(4-chlorophenyl)-7h-purin-6-amine Chemical compound C1=CC(Cl)=CC=C1NC1=NC(Cl)=NC2=C1N=CN2 IBCZOXNKMXUTOG-UHFFFAOYSA-N 0.000 description 1
- SUHSVYQLBGBINJ-UHFFFAOYSA-N 2-chloro-n-(4-chlorophenyl)-9-ethylpurin-6-amine Chemical compound N1=C(Cl)N=C2N(CC)C=NC2=C1NC1=CC=C(Cl)C=C1 SUHSVYQLBGBINJ-UHFFFAOYSA-N 0.000 description 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
- ZEUUTMRKMHVAIG-UHFFFAOYSA-N 2-oxooxolane-3-carboxylic acid Chemical compound OC(=O)C1CCOC1=O ZEUUTMRKMHVAIG-UHFFFAOYSA-N 0.000 description 1
- CJJLJBFJNXMANZ-UHFFFAOYSA-N 4,6-dichloro-2-propylsulfanylpyrimidin-5-amine Chemical compound CCCSC1=NC(Cl)=C(N)C(Cl)=N1 CJJLJBFJNXMANZ-UHFFFAOYSA-N 0.000 description 1
- GVPOUARKWLRVJJ-UHFFFAOYSA-N 4,6-dichloro-5-(2-chloroethyl)-2-methylsulfanylpyrimidine Chemical compound CSC1=NC(Cl)=C(CCCl)C(Cl)=N1 GVPOUARKWLRVJJ-UHFFFAOYSA-N 0.000 description 1
- DDEDQHVHVPJFAC-UHFFFAOYSA-N 4,6-dichloro-5-nitro-2-propylsulfanylpyrimidine Chemical compound CCCSC1=NC(Cl)=C([N+]([O-])=O)C(Cl)=N1 DDEDQHVHVPJFAC-UHFFFAOYSA-N 0.000 description 1
- OYYBICKMSRYMGS-UHFFFAOYSA-N 4-(4-chloroanilino)-6-morpholin-4-yl-5-nitropyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N2CCOCC2)C([N+](=O)[O-])=C1NC1=CC=C(Cl)C=C1 OYYBICKMSRYMGS-UHFFFAOYSA-N 0.000 description 1
- RZGNGADWHGMGGN-UHFFFAOYSA-N 4-(6-chloro-5-nitro-2-propylsulfanylpyrimidin-4-yl)morpholine Chemical compound CCCSC1=NC(Cl)=C([N+]([O-])=O)C(N2CCOCC2)=N1 RZGNGADWHGMGGN-UHFFFAOYSA-N 0.000 description 1
- FXDPPWYXCUOWOI-UHFFFAOYSA-N 4-[9-(2-chlorophenyl)-2-propylsulfanylpurin-6-yl]morpholine Chemical compound C=12N=CN(C=3C(=CC=CC=3)Cl)C2=NC(SCCC)=NC=1N1CCOCC1 FXDPPWYXCUOWOI-UHFFFAOYSA-N 0.000 description 1
- PMJAYWWFCGPNMX-UHFFFAOYSA-N 4-[9-(2-chlorophenyl)-2-propylsulfonylpurin-6-yl]morpholine Chemical compound C=12N=CN(C=3C(=CC=CC=3)Cl)C2=NC(S(=O)(=O)CCC)=NC=1N1CCOCC1 PMJAYWWFCGPNMX-UHFFFAOYSA-N 0.000 description 1
- WEGGBXZHIWVHOI-UHFFFAOYSA-N 4-chloro-2-methylsulfanyl-7h-pyrrolo[2,3-d]pyrimidine Chemical compound CSC1=NC(Cl)=C2C=CNC2=N1 WEGGBXZHIWVHOI-UHFFFAOYSA-N 0.000 description 1
- XQKBYZWMUFUNMD-UHFFFAOYSA-N 4-chloro-7-(4-chlorophenyl)-2-methylsulfanyl-5,6-dihydropyrrolo[2,3-d]pyrimidine Chemical compound C1CC=2C(Cl)=NC(SC)=NC=2N1C1=CC=C(Cl)C=C1 XQKBYZWMUFUNMD-UHFFFAOYSA-N 0.000 description 1
- FYVWMQMPTRZETB-UHFFFAOYSA-N 4-chloro-7-(4-chlorophenyl)-2-methylsulfonyl-5,6-dihydropyrrolo[2,3-d]pyrimidine Chemical compound C1CC=2C(Cl)=NC(S(=O)(=O)C)=NC=2N1C1=CC=C(Cl)C=C1 FYVWMQMPTRZETB-UHFFFAOYSA-N 0.000 description 1
- UGDSPYONQTWGFF-UHFFFAOYSA-N 4-chloro-7-(4-chlorophenyl)-5,6-dihydropyrrolo[2,3-d]pyrimidine-2-carbonitrile Chemical compound C1=CC(Cl)=CC=C1N1C(N=C(N=C2Cl)C#N)=C2CC1 UGDSPYONQTWGFF-UHFFFAOYSA-N 0.000 description 1
- DWGNEXUQCWQDBP-UHFFFAOYSA-N 4-chloro-7-ethyl-2-methylsulfanylpyrrolo[2,3-d]pyrimidine Chemical compound N1=C(SC)N=C2N(CC)C=CC2=C1Cl DWGNEXUQCWQDBP-UHFFFAOYSA-N 0.000 description 1
- SATHXOVBIHGCRP-UHFFFAOYSA-N 5-(2-hydroxyethyl)-2-methylsulfanyl-1h-pyrimidine-4,6-dione Chemical compound CSC1=NC(=O)C(CCO)C(=O)N1 SATHXOVBIHGCRP-UHFFFAOYSA-N 0.000 description 1
- CREXWCGCJMGNGJ-UHFFFAOYSA-N 5-(2-hydroxyethyl)-2-sulfanylidene-1,3-diazinane-4,6-dione Chemical compound OCCC1C(=O)NC(=S)NC1=O CREXWCGCJMGNGJ-UHFFFAOYSA-N 0.000 description 1
- HLVUUIRENGTYML-UHFFFAOYSA-N 5-amino-4-(4-chloroanilino)-6-(ethylamino)pyrimidine-2-carbonitrile Chemical compound CCNC1=NC(C#N)=NC(NC=2C=CC(Cl)=CC=2)=C1N HLVUUIRENGTYML-UHFFFAOYSA-N 0.000 description 1
- GJHNZJNXSKYROP-UHFFFAOYSA-N 5-amino-4-(4-chloroanilino)-6-morpholin-4-ylpyrimidine-2-carbonitrile Chemical compound N1=C(C#N)N=C(N2CCOCC2)C(N)=C1NC1=CC=C(Cl)C=C1 GJHNZJNXSKYROP-UHFFFAOYSA-N 0.000 description 1
- ZPNKNYVTVMKTRQ-UHFFFAOYSA-N 6-chloro-9-(4-chlorophenyl)-2-propylsulfanylpurine Chemical compound C12=NC(SCCC)=NC(Cl)=C2N=CN1C1=CC=C(Cl)C=C1 ZPNKNYVTVMKTRQ-UHFFFAOYSA-N 0.000 description 1
- UXSILEJMSZDVHE-UHFFFAOYSA-N 6-chloro-9-(4-chlorophenyl)-2-propylsulfonylpurine Chemical compound C12=NC(S(=O)(=O)CCC)=NC(Cl)=C2N=CN1C1=CC=C(Cl)C=C1 UXSILEJMSZDVHE-UHFFFAOYSA-N 0.000 description 1
- DLMQRKBQNCCUHU-UHFFFAOYSA-N 7-(4-chlorophenyl)-2,4-bis(ethylsulfonyl)pyrrolo[2,3-d]pyrimidine Chemical compound C12=NC(S(=O)(=O)CC)=NC(S(=O)(=O)CC)=C2C=CN1C1=CC=C(Cl)C=C1 DLMQRKBQNCCUHU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229940122805 Cathepsin S inhibitor Drugs 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- FDKLLWKMYAMLIF-UHFFFAOYSA-N cyclopropane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CC1 FDKLLWKMYAMLIF-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- PYXBXOJGGWLAKD-UHFFFAOYSA-N dimethoxymethyl acetate Chemical compound COC(OC)OC(C)=O PYXBXOJGGWLAKD-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- PHWISQNXPLXQRU-UHFFFAOYSA-N n,n-dimethylcarbamothioyl chloride Chemical compound CN(C)C(Cl)=S PHWISQNXPLXQRU-UHFFFAOYSA-N 0.000 description 1
- SAPXQPRWYUQUQQ-UHFFFAOYSA-N n-(2-chlorophenyl)-6-morpholin-4-yl-5-nitro-2-propylsulfanylpyrimidin-4-amine Chemical compound [O-][N+](=O)C=1C(N2CCOCC2)=NC(SCCC)=NC=1NC1=CC=CC=C1Cl SAPXQPRWYUQUQQ-UHFFFAOYSA-N 0.000 description 1
- PTXJARKGECZAST-UHFFFAOYSA-N n-(4-chlorophenyl)-6-morpholin-4-yl-5-nitro-2-propylsulfanylpyrimidin-4-amine Chemical compound [O-][N+](=O)C=1C(N2CCOCC2)=NC(SCCC)=NC=1NC1=CC=C(Cl)C=C1 PTXJARKGECZAST-UHFFFAOYSA-N 0.000 description 1
- SJBZJMBEANVQDC-UHFFFAOYSA-N n-(4-chlorophenyl)-7-ethyl-2-methylsulfanylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N1=C(SC)N=C2N(CC)C=CC2=C1NC1=CC=C(Cl)C=C1 SJBZJMBEANVQDC-UHFFFAOYSA-N 0.000 description 1
- SIDVENLOGUQLCJ-UHFFFAOYSA-N n-(4-chlorophenyl)-7-ethyl-2-methylsulfonylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N1=C(S(C)(=O)=O)N=C2N(CC)C=CC2=C1NC1=CC=C(Cl)C=C1 SIDVENLOGUQLCJ-UHFFFAOYSA-N 0.000 description 1
- ZTYPQOOTXXPFFN-UHFFFAOYSA-N n-(4-chlorophenyl)-9-ethyl-2-methylsulfanylpurin-6-amine Chemical compound N1=C(SC)N=C2N(CC)C=NC2=C1NC1=CC=C(Cl)C=C1 ZTYPQOOTXXPFFN-UHFFFAOYSA-N 0.000 description 1
- ZWDUMYSDRYHNAN-UHFFFAOYSA-N n-(4-chlorophenyl)-9-ethyl-2-methylsulfonylpurin-6-amine Chemical compound N1=C(S(C)(=O)=O)N=C2N(CC)C=NC2=C1NC1=CC=C(Cl)C=C1 ZWDUMYSDRYHNAN-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201980A SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Novel compounds |
| SE0201980 | 2002-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2279162T3 true ES2279162T3 (es) | 2007-08-16 |
Family
ID=20288336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03761002T Expired - Lifetime ES2279162T3 (es) | 2002-06-24 | 2003-06-23 | Nuevos purin- o pirrolo(2,3-d)pirimidin-2-carbonitrilos para tratar enfermedades asociadas con actividad de cisteina proteasa. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7439240B2 (enExample) |
| EP (1) | EP1532148B1 (enExample) |
| JP (1) | JP2005533804A (enExample) |
| AU (1) | AU2003243096A1 (enExample) |
| DE (1) | DE60311272T2 (enExample) |
| ES (1) | ES2279162T3 (enExample) |
| SE (1) | SE0201980D0 (enExample) |
| WO (1) | WO2004000843A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117396D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201980D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| RS20050532A (sr) * | 2003-01-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija |
| SI1599468T1 (sl) | 2003-01-14 | 2008-02-29 | Arena Pharm Inc | 1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| KR20060056944A (ko) | 2003-07-14 | 2006-05-25 | 아레나 파마슈티칼스, 인크. | 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료 |
| EP1724264A1 (en) * | 2004-03-10 | 2006-11-22 | Ono Pharmaceutical Co., Ltd. | Nitriles and medicinal compositions containing the same as the active ingredient |
| TW200614993A (en) | 2004-06-11 | 2006-05-16 | Akzo Nobel Nv | 4-phenyl-pyrimidine-2-carbonitrile derivatives |
| US7326715B2 (en) | 2005-09-23 | 2008-02-05 | N.V. Organon | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| TW200745055A (en) * | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| TW200734338A (en) * | 2006-01-16 | 2007-09-16 | Organon Nv | 6-Phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives |
| US7687515B2 (en) | 2006-01-17 | 2010-03-30 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| CN101479269A (zh) * | 2006-06-23 | 2009-07-08 | 阿斯利康(瑞典)有限公司 | 蝶啶衍生物及其作为组织蛋白酶抑制剂的用途 |
| US20080269241A1 (en) * | 2007-02-15 | 2008-10-30 | Darin Allen | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20090118274A1 (en) * | 2007-02-15 | 2009-05-07 | Darin Allen | Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20090099157A1 (en) * | 2007-02-15 | 2009-04-16 | Ameriks Michael K | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s |
| US20080200454A1 (en) * | 2007-02-15 | 2008-08-21 | Ameriks Michael K | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| US20080207683A1 (en) * | 2007-02-15 | 2008-08-28 | Darin Allen | Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
| EP1972630A1 (en) * | 2007-03-02 | 2008-09-24 | Glaxo Group Limited | Purines as cysteine protease inhibitors |
| WO2008107368A1 (en) * | 2007-03-02 | 2008-09-12 | Glaxo Group Limited | Purines as cysteine protease inhibitors |
| US7932251B2 (en) | 2007-07-16 | 2011-04-26 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| TW200911803A (en) * | 2007-07-16 | 2009-03-16 | Organon Nv | 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives |
| WO2009107767A1 (ja) * | 2008-02-29 | 2009-09-03 | 大日本住友製薬株式会社 | Ｈ４受容体アンタゴニスト作用を有する新規２環性ピリミジン誘導体 |
| EP2297153B1 (en) * | 2008-04-21 | 2015-05-27 | Lexicon Pharmaceuticals, Inc. | Limk2 inhibitors, compositions comprising them, and methods of their use |
| WO2010059418A1 (en) * | 2008-11-19 | 2010-05-27 | The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services | Substituted triazine and purine compounds, methods of inhibiting cruzain and rhodesain and methods of treating chagas disease and african trypanosomiasis |
| US8026236B2 (en) | 2009-01-16 | 2011-09-27 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| TW201035094A (en) | 2009-01-16 | 2010-10-01 | Organon Nv | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| GB0917934D0 (en) | 2009-10-13 | 2009-11-25 | Syngenta Ltd | Herbicidal compounds |
| EP2523954B1 (en) | 2010-01-15 | 2014-04-16 | Merck Sharp & Dohme B.V. | 1h-[1,2,3]triazolo[4,5-c]pyridine-4- carbonitrile derivatives as cathepsin s inhibitors |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | 艾尼纳制药公司 | Gpr119受体调节剂和对与其相关的障碍的治疗 |
| ES2562274T3 (es) | 2010-10-06 | 2016-03-03 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| CA2870527A1 (en) * | 2012-04-17 | 2013-10-24 | Astellas Pharma Inc. | Nitrogenated bicyclic aromatic heterocyclic compound |
| EP3467124A1 (en) | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| CA2888122A1 (en) | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| CA2889572C (en) | 2012-11-08 | 2019-03-05 | Pfizer Inc. | Heteroaromatic compounds as dopamine d1 ligands |
| US20160032400A1 (en) | 2013-03-15 | 2016-02-04 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| EP3524698A1 (en) | 2013-10-09 | 2019-08-14 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| CA2946990A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine d1 ligands |
| MY195016A (en) | 2014-08-04 | 2023-01-03 | Nuevolution As | Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases |
| KR20170093182A (ko) | 2014-12-11 | 2017-08-14 | 인바이오모션 에스.엘. | 인간 c-maf에 대한 결합 구성원 |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩 |
| CA3025264A1 (en) | 2016-05-25 | 2017-11-30 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
| CA3082728A1 (en) | 2017-11-22 | 2019-05-31 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| KR102054910B1 (ko) * | 2017-12-19 | 2019-12-12 | 한림제약(주) | 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体に関連する状態を治療する方法 |
| AU2020250933A1 (en) | 2019-04-05 | 2021-10-28 | Centre Hospitalier Régional Et Universitaire De Brest | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| BR112022012205A2 (pt) | 2019-12-20 | 2022-09-13 | Nuevolution As | Compostos ativos para receptores nucleares |
| JP7713954B2 (ja) | 2020-03-31 | 2025-07-28 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
| CA3174252A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
| WO2024105159A1 (en) * | 2022-11-16 | 2024-05-23 | University Of Zurich | Ligands of the m6a-rna readers |
| CN121652156A (zh) * | 2024-09-13 | 2026-03-13 | 常州强力电子新材料股份有限公司 | 一种氮杂腺嘌呤化合物及其制备方法与应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200100972A1 (ru) * | 1999-03-15 | 2002-02-28 | Аксис Фармасьютикалз, Инк. | Новые соединения и композиции как ингибиторы протеаз |
| JP2001011037A (ja) * | 1999-07-01 | 2001-01-16 | Kissei Pharmaceut Co Ltd | シクロアルカンカルボン酸アミド誘導体 |
| AU2277201A (en) * | 1999-12-17 | 2001-06-25 | Ariad Pharmaceuticals, Inc. | Novel purines |
| BR0108002A (pt) * | 2000-02-04 | 2002-10-29 | Pfizer Prod Inc | Derivados de amidas heterocìclicas |
| US6921753B2 (en) * | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
| GB0015727D0 (en) * | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
| WO2002032879A1 (en) * | 2000-10-19 | 2002-04-25 | Naeja Pharmaceutical Inc. | Dihydropyrimidine derivatives as cysteine protease inhibitors |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201976D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0201980D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| GB0220187D0 (en) * | 2002-08-30 | 2002-10-09 | Novartis Ag | Organic compounds |
| AR043692A1 (es) | 2003-02-06 | 2005-08-10 | Novartis Ag | 2-cianopirrolopirimidinas y sus usos farmaceuticos |
| GB0304640D0 (en) | 2003-02-28 | 2003-04-02 | Novartis Ag | Organic compounds |
| EP1724264A1 (en) | 2004-03-10 | 2006-11-22 | Ono Pharmaceutical Co., Ltd. | Nitriles and medicinal compositions containing the same as the active ingredient |
| WO2006040300A1 (en) | 2004-10-12 | 2006-04-20 | N.V. Organon | 4-cycloalkyl-pyrimidine-2-carbonitrile derivatives |
-
2002
- 2002-06-24 SE SE0201980A patent/SE0201980D0/xx unknown
-
2003
- 2003-06-23 JP JP2004515329A patent/JP2005533804A/ja active Pending
- 2003-06-23 US US10/518,815 patent/US7439240B2/en not_active Expired - Fee Related
- 2003-06-23 DE DE60311272T patent/DE60311272T2/de not_active Expired - Fee Related
- 2003-06-23 ES ES03761002T patent/ES2279162T3/es not_active Expired - Lifetime
- 2003-06-23 AU AU2003243096A patent/AU2003243096A1/en not_active Abandoned
- 2003-06-23 EP EP03761002A patent/EP1532148B1/en not_active Expired - Lifetime
- 2003-06-23 WO PCT/SE2003/001079 patent/WO2004000843A1/en not_active Ceased
-
2008
- 2008-02-01 US US12/024,375 patent/US20080125426A1/en not_active Abandoned
- 2008-02-01 US US12/024,423 patent/US20080119469A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004000843A1 (en) | 2003-12-31 |
| EP1532148B1 (en) | 2007-01-17 |
| AU2003243096A1 (en) | 2004-01-06 |
| US20050203107A1 (en) | 2005-09-15 |
| US20080125426A1 (en) | 2008-05-29 |
| US20080119469A1 (en) | 2008-05-22 |
| DE60311272D1 (de) | 2007-03-08 |
| US7439240B2 (en) | 2008-10-21 |
| DE60311272T2 (de) | 2007-11-15 |
| JP2005533804A (ja) | 2005-11-10 |
| SE0201980D0 (sv) | 2002-06-24 |
| EP1532148A1 (en) | 2005-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7439240B2 (en) | Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity | |
| AU2021245168B2 (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| ES2280794T3 (es) | Nuevo uso de pirimidin- o triazin-2-carbonitrilos para tratar enfermedades asociadas con la actividad de cisteina proteasa, y nuevos derivados de pirimidin-2-carbonitrilo. | |
| ES2931150T3 (es) | Inhibidores de la interacción YAP/TAZ-TEAD y su uso en el tratamiento del cáncer | |
| ES2650013T3 (es) | Pirimidopirimidinonas útiles como inhibidores de la quinasa Wee-1 | |
| JP2023179774A (ja) | がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物 | |
| ES2335659T3 (es) | Pirimidopirimidonas como inhibidores de quinasas. | |
| KR20250070059A (ko) | 신규한 테트라헤테로사이클 화합물 | |
| ES2645371T3 (es) | Compuestos orgánicos | |
| ES2711936T3 (es) | Inhibidores de la tirosina cinasa de Bruton | |
| TW202317570A (zh) | 三環化合物 | |
| CA3199082A1 (en) | Heterocyclic spiro compounds and methods of use | |
| US20130018032A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| ES2620119T3 (es) | Derivados heterocíclicos novedosos como moduladores de la actividad de quinasa | |
| ES3019235T3 (en) | Heterocyclic compounds capable of activating sting | |
| JP2016503049A (ja) | 治療用に活性なピラゾロ−ピリミジン誘導体 | |
| AU2018364708A1 (en) | Sting modulator compounds, and methods of making and using | |
| ES2635262T3 (es) | Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas | |
| ES2978573T3 (es) | Compuestos antibacterianos | |
| CA2952992A1 (en) | Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor | |
| JP2017518384A (ja) | キナーゼ阻害剤としての縮合二環式ヘテロ芳香族誘導体 | |
| CA2603163A1 (en) | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives | |
| JP2017518385A (ja) | キナーゼ阻害剤としての縮合二環式ヘテロ芳香族誘導体 | |
| CN112584898A (zh) | P2x3受体拮抗剂 | |
| ES2687450T3 (es) | Nuevo derivado de furanona |